Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Shore Capital slashes forecasts for Greggs, sees stock 'treading water'

(Sharecast News) - The share price of Greggs tanked on Wednesday after the fast food bakery chain warned of lower profits this year, with Shore Capital saying it expects the stock to "tread water" for the foreseeable future. The broker kept a 'hold' rating on the stock, which was down 15% at 1,683p by 1400 BST, taking its year-to-date loss to 40%.

In an unscheduled trading update, Greggs revealed that FY25 EBIT may be "modestly below" the £195.3m achieved in FY24 despite sales growth in the first half.

The company said it had made "good progress" in May but noted this was followed by "slower growth" in June as high temperatures affected the UK, increasing demand for cold drinks but reducing overall footfall.

Shore Capital said the update "makes for unpleasant reading" with like-for-like growth of 4% in May curtailed by recent hot weather.

"We believe June's LFL sales have been barely positive, so a mid-single digit volume decline, a perfect storm for an integrated manufacturer/retailer," the broker said.

Shore Capital has now lowered its FY25 EBIT forecast to 5% below the FY24 result, equating to a 9% downgrade to £186m.

"We reiterate our view that Greggs is a very high-quality business, with a strong management team and relative value/quality position on the high street that is amongst the leading pack in Food to Go," the broker said.

"However, after a sustained hot streak we forecast a more subdued financial outcome over the medium term and see the stock treading water for some time."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.